Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study

The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect of pneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimate the direct costs of hospitalized IPD cases. A prospective study was made in children aged <5 years diagno...

ver descrição completa

Detalhes bibliográficos
Autores: Hernández S, Navas E, Aznar, I., Ciruela P, García, J., Moraga-Llop F, Muñoz, C., Codina G, Fernández de Sevilla, M., González-Peris S, Esteva, C., Planes AM, Izquierdo C, Martínez, J., Campins M, Uriona S, Salleras L, Serrano, A., Jané M, Domínguez A
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Recursos:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p17958
Acesso em linha:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17958
Access Level:acceso abierto
Palavra-chave:PCV7
PCV13
invasive pneumococcal disease
direct cost
id ES_90ec1fd5287c90b28f75e89eceff5baf
oai_identifier_str oai:fsjd.fundanetsuite.com:p17958
network_acronym_str ES
network_name_str España
spelling Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study Hernández S Navas E Aznar, I. Ciruela P García, J. Moraga-Llop F Muñoz, C. Codina G Fernández de Sevilla, M. González-Peris S Esteva, C. Planes AM Izquierdo C Martínez, J. Campins M Uriona S Salleras L Serrano, A. Jané M Domínguez A PCV7 PCV13 invasive pneumococcal disease direct cost The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect of pneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimate the direct costs of hospitalized IPD cases. A prospective study was made in children aged <5 years diagnosed with IPD in two high-tech hospitals in Catalonia (Spain) between 2007-2009 (PCV7 period) and 2012-2015 (PCV13 period). Costs were calculated according to 2014 Catalan Health Service rates using diagnostic-related groups. In total, 319 and 154 cases were collected, respectively. Pneumonia had the highest cost (65.7% and 62.0%, respectively), followed by meningitis (25.8% and 26.1%, respectively). During 2007-2015, the costs associated with PCV7 serotypes (Pearson coefficient (Pc) = -0.79;p= 0.036) and additional PCV13 serotypes (Pc = -0.75;p= 0.05) decreased, but those of other serotypes did not (Pc = 0.23p= 0.62). The total mean cost of IPD increased in the PCV13 period by 31.4% (euro3016.1 vs. euro3963.9), mainly due to ICU stay (77.4%; euro1051.4 vs. euro1865.6). During the PCV13 period, direct IPD costs decreased due to a reduction in the number of cases, but cases were more severe and had a higher mean cost. During 2015, IPD costs increased due to an increase in the costs associated with non-PCV13 serotypes and serotype 3 and this requires further investigation. MDPI https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17958
title Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
spellingShingle Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
Hernández S
PCV7
PCV13
invasive pneumococcal disease
direct cost
title_short Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
title_full Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
title_fullStr Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
title_full_unstemmed Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
title_sort Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study
author Hernández S
author_facet Hernández S
Navas E
Aznar, I.
Ciruela P
García, J.
Moraga-Llop F
Muñoz, C.
Codina G
Fernández de Sevilla, M.
González-Peris S
Esteva, C.
Planes AM
Izquierdo C
Martínez, J.
Campins M
Uriona S
Salleras L
Serrano, A.
Jané M
Domínguez A
author_role author
author2 Navas E
Aznar, I.
Ciruela P
García, J.
Moraga-Llop F
Muñoz, C.
Codina G
Fernández de Sevilla, M.
González-Peris S
Esteva, C.
Planes AM
Izquierdo C
Martínez, J.
Campins M
Uriona S
Salleras L
Serrano, A.
Jané M
Domínguez A
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
topic PCV7
PCV13
invasive pneumococcal disease
direct cost
topic_facet PCV7
PCV13
invasive pneumococcal disease
direct cost
description The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect of pneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimate the direct costs of hospitalized IPD cases. A prospective study was made in children aged <5 years diagnosed with IPD in two high-tech hospitals in Catalonia (Spain) between 2007-2009 (PCV7 period) and 2012-2015 (PCV13 period). Costs were calculated according to 2014 Catalan Health Service rates using diagnostic-related groups. In total, 319 and 154 cases were collected, respectively. Pneumonia had the highest cost (65.7% and 62.0%, respectively), followed by meningitis (25.8% and 26.1%, respectively). During 2007-2015, the costs associated with PCV7 serotypes (Pearson coefficient (Pc) = -0.79;p= 0.036) and additional PCV13 serotypes (Pc = -0.75;p= 0.05) decreased, but those of other serotypes did not (Pc = 0.23p= 0.62). The total mean cost of IPD increased in the PCV13 period by 31.4% (euro3016.1 vs. euro3963.9), mainly due to ICU stay (77.4%; euro1051.4 vs. euro1865.6). During the PCV13 period, direct IPD costs decreased due to a reduction in the number of cases, but cases were more severe and had a higher mean cost. During 2015, IPD costs increased due to an increase in the costs associated with non-PCV13 serotypes and serotype 3 and this requires further investigation.
publishDate 2020
format article
status_str publishedVersion
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17958
eu_rights_str_mv openAccess
publisher MDPI
institution Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
_version_ 1878437870964834305
publishDateSort 2020
author_browse Aznar, I.
Campins M
Ciruela P
Codina G
Domínguez A
Esteva, C.
Fernández de Sevilla, M.
García, J.
González-Peris S
Hernández S
Izquierdo C
Jané M
Martínez, J.
Moraga-Llop F
Muñoz, C.
Navas E
Planes AM
Salleras L
Serrano, A.
Uriona S
publisherStr MDPI
score 6,924472